Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

PURPOSE: To assess the overall survival (OS) of early human epidermal growth factor receptor 2 (HER2)-enriched breast cancer patients after receiving neoadjuvant trastuzumab (NAT) compared to adjuvant trastuzumab (AT) treatment and the difference in local-regional relapse (LRR) rate with this tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Lin, Wu, Qian, Xiong, Jing, Su, Zhumin, Zhang, Biyuan, Song, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718741/
https://www.ncbi.nlm.nih.gov/pubmed/31507328
http://dx.doi.org/10.2147/CMAR.S208319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718741/
https://www.ncbi.nlm.nih.gov/pubmed/31507328
http://dx.doi.org/10.2147/CMAR.S208319

Ejemplares similares